[[ type === 'moc' ? 'MARKET ON CLOSE' : 'FREE WEBINAR' ]]
[[ timeLabel ]] WATCH LIVE:
Your browser of choice has not been tested for use with Barchart.com. If you have issues, please download one of the browsers listed here.
Jump-Start Your Search For Promising Trade Ideas With Barchart Premier’s "Top Stock Pick". FREE 30 Day Trial
Stocks | Futures | Watchlist | News | More
or
Faster, Cleaner, Better.

Monte Rosa Therapeutics Inc (GLUE)

Monte Rosa Therapeutics Inc (GLUE)
[[ item.lastPrice ]] [[ item.priceChange ]] ([[ item.percentChange ]]) [[ item.tradeTime ]] [NASDAQ]
[[ item.bidPrice ]] x [[ item.bidSize ]] [[ item.askPrice ]] x [[ item.askSize ]]
[[ session ]] by (Cboe BZX)
[[ item.lastPrice ]] [[ item.priceChange ]] ([[ item.percentChange ]]) [[ item.tradeTime ]] [NASDAQ]
[[ item.bidPrice ]] x [[ item.bidSize ]] [[ item.askPrice ]] x [[ item.askSize ]]
[[ session ]] [[ item.lastPriceExt ]] [[ item.priceChangeExt ]] ([[ item.percentChangeExt ]]) [[ item.tradeTimeExt ]]
Quote Overview for [[ item.sessionDateDisplayLong ]]
[[ rowChartData.labelLow ]]
[[ rowChartData.lowPriceFormatted ]]
[[ rowChartData.lowPrice ]]
[[ rowChartData.labelHigh ]]
[[ rowChartData.highPriceFormatted ]]
[[ rowChartData.highPrice ]]
since [[ rowChartData.lowDate ]]
since [[ rowChartData.highDate ]]
[[ value ]] [[ value ]] ([[ financialData.relativeStrengthDirection14d ]]) ([[ financialData.highPercent1y ]]) ([[ financialData.lowPercent1y ]])
Realtime quote and/or trades are not sourced from all markets.

Fundamentals

See More
  • Market Capitalization, $K 1,466,555
  • Shares Outstanding, K 84,479
  • Annual Sales, $ 123,670 K
  • Annual Income, $ -38,630 K
  • EBIT $ -148 M
  • EBITDA $ -140 M
  • 60-Month Beta 1.60
  • Price/Sales 12.02
  • Price/Cash Flow N/A
  • Price/Book 2.84

Options Overview Details

View History
  • Implied Volatility 108.62% (-15.42%)
  • Historical Volatility 52.23%
  • IV Percentile 50%
  • IV Rank 13.48%
  • IV High 357.38% on 07/15/25
  • IV Low 69.86% on 01/27/26
  • Expected Move (DTE 13) 0.17 (1.04%)
  • Put/Call Vol Ratio 0.50
  • Today's Volume 6
  • Volume Avg (30-Day) 72
  • Put/Call OI Ratio 0.14
  • Today's Open Interest 4,215
  • Open Int (30-Day) 3,783
  • Expected Range 16.20 to 16.54

Analyst Rating / Earnings Estimates

Current Rating
See More
Strong Buy
Based on 9 analysts offering recommendations.
Earnings Estimates - Current Qtr 06/30/26
See More
  • Average Estimate $-0.25
  • Number of Estimates 3
  • High Estimate $0.04
  • Low Estimate $-0.44
  • Prior Year $-0.15
  • Growth Rate Est. (year over year) -66.67%

Price Performance

See More
Period Period Low Period High Performance
1-Month
16.25 +0.74%
on 06/05/26
21.27 -23.04%
on 05/11/26
-2.98 (-15.40%)
since 05/05/26
3-Month
14.20 +15.28%
on 03/24/26
21.62 -24.28%
on 04/22/26
-1.58 (-8.80%)
since 03/05/26
52-Week
4.12 +297.33%
on 08/08/25
25.77 -36.48%
on 01/08/26
+11.75 (+254.33%)
since 06/05/25

Most Recent Stories

More News
Monte Rosa Reports Inducement Grants Under Nasdaq Listing Rule 5635(c)(4)

BOSTON, June 02, 2026 (GLOBE NEWSWIRE) -- Monte Rosa Therapeutics, Inc. (Nasdaq: GLUE),  a clinical-stage biotechnology company developing novel molecular glue degrader (MGD)-based medicines, today...

GLUE : 16.37 (-5.70%)
Monte Rosa Therapeutics to Participate in Upcoming Investor Conferences

BOSTON, May 20, 2026 (GLOBE NEWSWIRE) -- Monte Rosa Therapeutics, Inc. (Nasdaq: GLUE), a clinical-stage biotechnology company developing novel molecular glue degrader (MGD)-based medicines, today...

GLUE : 16.37 (-5.70%)
Monte Rosa Therapeutics: Q1 Earnings Snapshot

Monte Rosa Therapeutics: Q1 Earnings Snapshot

GLUE : 16.37 (-5.70%)
Monte Rosa Therapeutics Announces First Quarter 2026 Financial Results and Business Updates

Interim clinical data from GFORCE-1 trial of NEK7-directed MGD MRT-8102 demonstrated profound CRP reductions in subjects with elevated CVD risk; readout of expanded GFORCE-1 trial in subjects with elevated...

GLUE : 16.37 (-5.70%)
Monte Rosa Reports Inducement Grants Under Nasdaq Listing Rule 5635(c)(4)

BOSTON, May 05, 2026 (GLOBE NEWSWIRE) -- Monte Rosa Therapeutics, Inc. (Nasdaq: GLUE), a clinical-stage biotechnology company developing novel molecular glue degrader (MGD)-based medicines, today announced the...

GLUE : 16.37 (-5.70%)
Monte Rosa Therapeutics Presents Preclinical Data at American Association for Cancer Research (AACR) Annual Meeting 2026 on the Potential of its Cyclin E1 (CCNE1)-directed Molecular Glue Degrader to Treat CCNE1-amplified Solid Tumors

CCNE1-directed molecular glue degrader (MGD) induced deep tumor regressions in CCNE1-amplified in vivo models of ovarian, breast, and gastric cancers  CCNE1-directed MGD demonstrated superior selectivity...

GLUE : 16.37 (-5.70%)
Monte Rosa Therapeutics: Q4 Earnings Snapshot

Monte Rosa Therapeutics: Q4 Earnings Snapshot

GLUE : 16.37 (-5.70%)
Monte Rosa Therapeutics Announces Fourth Quarter and Full-Year 2025 Financial Results and Business Updates

Positive interim Phase 1 data of NEK7-directed MGD MRT-8102 demonstrated profound CRP reductions in elevated CVD-risk subjects; readout of expanded part 3 CRP PoC trial (now called GFORCE-1) anticipated...

GLUE : 16.37 (-5.70%)
Monte Rosa Therapeutics Announces Clinical Supply Agreement to Support Phase 2 Trial Evaluating MRT-2359 in Combination with Apalutamide for the Treatment of Metastatic Castration-Resistant Prostate Cancer

MRT-2359 is an investigational, orally bioavailable, GSPT1-directed molecular glue degrader that has shown compelling clinical activity in combination with androgen receptor (AR) inhibition in heavily...

GLUE : 16.37 (-5.70%)
Monte Rosa Therapeutics Presents Updated Clinical Data from Phase 1/2 Study of MRT-2359 in Combination with Enzalutamide in Heavily Pretreated Metastatic Castration-Resistant Prostate Cancer Patients at ASCO Genitourinary Cancers Symposium (ASCO GU)

In mCRPC patients with androgen receptor (AR) mutations, treatment with MRT-2359 in combination with  enzalutamide led to a 100% PSA response rate (5 of 5 patients) and a 100% disease control rate, including...

GLUE : 16.37 (-5.70%)

Barchart Technical Opinion

The Barchart Technical Opinion rating is a 8% Sell with a Weakening short term outlook on maintaining the current direction.

See More Share

Business Summary

Monte Rosa Therapeutics Inc. is a biotechnology company. It involved in developing a portfolio of novel small molecule precision medicines which employ the body's natural mechanisms to selectively degrade therapeutically relevant proteins. Monte Rosa Therapeutics Inc. is based in BOSTON.

See More

Key Turning Points

3rd Resistance Point 18.91
2nd Resistance Point 18.36
1st Resistance Point 17.36
Last Price 16.37
1st Support Level 15.81
2nd Support Level 15.26
3rd Support Level 14.26

See More

52-Week High 25.77
Fibonacci 61.8% 17.50
Last Price 16.37
Fibonacci 50% 14.94
Fibonacci 38.2% 12.39
52-Week Low 4.12

See More

Want to use this as
your default charts setting?
Save this setup as a Chart Templates
Switch the Market flag
for targeted data from your country of choice.
Open the menu and switch the
Market flag for targeted data from your country of choice.
Want Streaming Chart Updates?
Switch your Site Preferences
to use Interactive Charts
Need More Chart Options?
Right-click on the chart to open the Interactive Chart menu.
Use your up/down arrows to move through the symbols.